394 related articles for article (PubMed ID: 33357454)
1. Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site.
Chen S; Wu JL; Liang Y; Tang YG; Song HX; Wu LL; Xing YF; Yan N; Li YT; Wang ZY; Xiao SJ; Lu X; Chen SJ; Lu M
Cancer Cell; 2021 Feb; 39(2):225-239.e8. PubMed ID: 33357454
[TBL] [Abstract][Full Text] [Related]
2. Broad-spectrum rescue compounds for structural p53 mutations: perspective on 'Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site'.
Wu JL; Chen S; Lu M
J Mol Cell Biol; 2021 May; 13(2):155-157. PubMed ID: 33508133
[No Abstract] [Full Text] [Related]
3. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase.
Yoda A; Toyoshima K; Watanabe Y; Onishi N; Hazaka Y; Tsukuda Y; Tsukada J; Kondo T; Tanaka Y; Minami Y
J Biol Chem; 2008 Jul; 283(27):18969-79. PubMed ID: 18482988
[TBL] [Abstract][Full Text] [Related]
4. CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia.
Zhang T; Ma D; Wei D; Lu T; Yu K; Zhang Z; Wang W; Fang Q; Wang J
Anticancer Drugs; 2020 Feb; 31(2):158-168. PubMed ID: 31584454
[TBL] [Abstract][Full Text] [Related]
5. AcGlcAs: A Novel P53-Targeting Arsenical with Potent Cellular Uptake and Cancer Cell Selectivity.
Liang Y; An Q; Song H; Tang Y; Xiao S; Wu J; Yan N; Yu B; Cao X; Lu M
J Med Chem; 2023 Dec; 66(24):16579-16596. PubMed ID: 38069817
[TBL] [Abstract][Full Text] [Related]
6. TP53 inhibitor PFTα increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells.
Wang H; Wang X; Xu L; Zhang J
FEBS Open Bio; 2022 Mar; 12(3):616-626. PubMed ID: 35030298
[TBL] [Abstract][Full Text] [Related]
7. Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts.
Maimaitiyiming Y; Zhu HH; Yang C; Naranmandura H
Drug Metab Rev; 2020 Aug; 52(3):425-437. PubMed ID: 32677488
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex.
Wang HY; Zhang B; Zhou JN; Wang DX; Xu YC; Zeng Q; Jia YL; Xi JF; Nan X; He LJ; Yue W; Pei XT
Cell Death Dis; 2019 Jun; 10(6):453. PubMed ID: 31186405
[TBL] [Abstract][Full Text] [Related]
9. Differential anticancer activities of arsenic trioxide on head and neck cancer cells with different human papillomavirus status.
Du S; Liu K; Gao P; Li Z; Zheng J
Life Sci; 2018 Nov; 212():182-193. PubMed ID: 30243648
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA ROR confers arsenic trioxide resistance to HepG2 cells by inhibiting p53 expression.
Li X; Sun D; Zhao T; Zhang Z
Eur J Pharmacol; 2020 Apr; 872():172982. PubMed ID: 32017938
[TBL] [Abstract][Full Text] [Related]
11. Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress.
Masciarelli S; Capuano E; Ottone T; Divona M; De Panfilis S; Banella C; Noguera NI; Picardi A; Fontemaggi G; Blandino G; Lo-Coco F; Fazi F
Leukemia; 2018 Feb; 32(2):285-294. PubMed ID: 28776567
[TBL] [Abstract][Full Text] [Related]
12. ATO stabilizes structural p53 mutants.
Gummlich L
Nat Rev Cancer; 2021 Mar; 21(3):141. PubMed ID: 33542522
[No Abstract] [Full Text] [Related]
13. MicroRNA-204 Potentiates the Sensitivity of Acute Myeloid Leukemia Cells to Arsenic Trioxide.
Wang Z; Fang Z; Lu R; Zhao H; Gong T; Liu D; Hong L; Ma J; Zhang M
Oncol Res; 2019 Sep; 27(9):1035-1042. PubMed ID: 30982490
[TBL] [Abstract][Full Text] [Related]
14. Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties.
Song H; Wu J; Tang Y; Dai Y; Xiang X; Li Y; Wu L; Wu J; Liang Y; Xing Y; Yan N; Li Y; Wang Z; Xiao S; Li J; Zheng D; Chen X; Fang H; Ye C; Ma Y; Wu Y; Wu W; Li J; Zhang S; Lu M
Sci Transl Med; 2023 Apr; 15(690):eabn9155. PubMed ID: 37018419
[TBL] [Abstract][Full Text] [Related]
15. ATR, PML, and CHK2 play a role in arsenic trioxide-induced apoptosis.
Joe Y; Jeong JH; Yang S; Kang H; Motoyama N; Pandolfi PP; Chung JH; Kim MK
J Biol Chem; 2006 Sep; 281(39):28764-71. PubMed ID: 16891316
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide decreases the amount and inhibits the function of regulatory T cells, which may contribute to its efficacy in the treatment of acute promyelocytic leukemia.
Xu W; Li X; Quan L; Yao J; Mu G; Guo J; Wang Y
Leuk Lymphoma; 2018 Mar; 59(3):650-659. PubMed ID: 28679299
[TBL] [Abstract][Full Text] [Related]
17. Arsenic and an Old Place: Rescuing p53 Mutants in Cancer.
Loh SN
Cancer Cell; 2021 Feb; 39(2):140-142. PubMed ID: 33561393
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide extends survival of Li-Fraumeni syndrome mimicking mouse.
Li J; Xiao S; Shi F; Song H; Wu J; Zheng D; Chen X; Tan K; Lu M
Cell Death Dis; 2023 Nov; 14(11):783. PubMed ID: 38030599
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression.
Yan W; Zhang Y; Zhang J; Liu S; Cho SJ; Chen X
J Biol Chem; 2011 May; 286(20):17478-86. PubMed ID: 21454520
[TBL] [Abstract][Full Text] [Related]
20. Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazone.
Esmaeili S; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Salari S; Gharehbaghian A; Hamidpour M; Bashash D
Int J Biochem Cell Biol; 2020 May; 122():105739. PubMed ID: 32169580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
